AGC Pharma Chemicals has opened a state-of-the-art manufacturing facility in Malgrat de Mar, Barcelona, following an investment of more than €100 million. The company, which specialises in active pharmaceutical ingredients (APIs) and intermediates, described the expansion as a ‘key milestone’ in its growth strategy.
The plant was formally inaugurated by Miquel Sàmper, Catalonia’s Minister for Business and Labour, alongside Japan’s Consul General in Barcelona, Akiko Shikata. Company leaders Jun Kurihara, CEO of AGC Pharma Chemicals, and Hideyuki Kurata, Chief Technology Officer of parent firm AGC Inc., also attended.
Spanning 7,500 square metres, the new site increases the company’s production capacity by 30 per cent and incorporates high-potency API technology classified at OEB5 safety level. The facility is designed to handle the full life cycle of drug development, from early-stage production through to large-scale manufacturing.
AGC highlighted the plant’s advanced technology as critical for meeting rising demand while ensuring safe and efficient management of highly potent pharmaceutical substances. The expansion underlines Barcelona’s growing importance as a hub for advanced life sciences and pharmaceutical manufacturing.
With its investment, AGC strengthens its position in Europe while bolstering Catalonia’s role in the global pharmaceutical supply chain. The plant is expected to serve both local and international markets, signalling long-term commitment to innovation and growth in the sector.
👉 Join our WhatsApp broadcast channel to get all of the latest news delivered to you
